Concepedia

A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan

Evolène Deslignière, Hélène Diemer, Stéphane Erb, Pierre Coliat, Xavier Pivot, Alexandre Detappe, Oscar Hernandez‐Alba, Sarah Cianférani

Frontiers in Bioscience-Landmark · 2022 · 16 citations · 37 references

DOIFull text

Open access

Abstract

This study illustrates the strengths and drawbacks of each LC-nMS coupling. By combining SEC-, HIC-, and CEX-nMS, we were able to achieve a comprehensive characterization of T-DXd without extensive sample preparation prior to MS analysis.

References

37

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research · 2008 · 1.6K citations

, , +12

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al. · Clinical Cancer Research · 2016 · 1K citations · Full text

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

New England Journal of Medicine · 2022 · 1K citations · Full text

Identification of multiple sources of charge heterogeneity in a recombinant antibody

Reed J. Harris, Bruce Kabakoff, Frank Macchi et al. · Journal of Chromatography B Biomedical Sciences and Applications · 2001 · 498 citations

, , +14

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

Robert P. Lyon, Tim D. Bovee, Svetlana O. Doronina et al. · Nature Biotechnology · 2015 · 498 citations

, , +8